Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Bipolar Disorder01:30

Bipolar Disorder

Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acceptability and safety of two sequential doses of psilocybin in bipolar II depression: protocol for an open-label single-arm feasibility study.

BMJ open·2026
Same author

Establishing a Specialty Bipolar Clinic: The National Network of Depression Centers Consensus Recommendations.

Bipolar disorders·2026
Same author

Decomposing neuroanatomical heterogeneity in depression: insights from an ENIGMA major depressive disorder working group study in 5146 individuals.

Translational psychiatry·2026
Same author

The Regional Vulnerability Index (RVI) as a Neuroimaging-Based Biomarker for Autism: Associations with Likelihood, Cognition, and Longitudinal Social Outcomes.

bioRxiv : the preprint server for biology·2026
Same author

Brain Morphology Mediators of the Association of Childhood Trauma With Bipolar Disorder: An International ENIGMA Bipolar Disorder Working Group Study.

JAMA psychiatry·2026
Same author

Response-predictive MRI biomarkers of low-dose lithium therapy: cortical thickness changes in patients with bipolar depression.

Psychiatry research. Neuroimaging·2026

Related Experiment Video

Updated: Jun 12, 2026

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

Emerging drugs for bipolar disorder.

Marsal Sanches1, Andrew R Newberg, Jair C Soares

  • 1UT Center of Excellence on Mood Disorders, Department of Psychiatry and Behavioral Sciences, UT Houston Medical School, #3210, Houston, TX 77054, USA.

Expert Opinion on Emerging Drugs
|May 22, 2010
PubMed
Summary

Novel pharmacological treatments show promise for bipolar disorder (BD), particularly for depressive episodes. Further research is needed to confirm their efficacy and role in managing this chronic mental illness.

Related Experiment Videos

Last Updated: Jun 12, 2026

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

Area of Science:

  • Psychiatry
  • Pharmacology
  • Neuroscience

Background:

  • Bipolar disorder (BD) is a chronic mental illness causing significant disability and suicide risk.
  • Current treatments offer insufficient management for many patients, leading to relapse and residual symptoms.

Purpose of the Study:

  • To review novel pharmacological treatments for bipolar disorder.
  • To explore emerging therapeutic strategies for managing BD phases and symptoms.

Main Methods:

  • Comprehensive literature review of PubMed (1990-2010) using 'bipolar disorder' and 'therapeutics' keywords.
  • Manual cross-referencing and screening of articles for novel BD treatments.

Main Results:

  • New pharmacological approaches are detailed, including mechanisms of action.
  • Potential applications in different BD phases and effects on cognitive impairment are discussed.

Conclusions:

  • Emerging drugs show promise, especially for bipolar depression.
  • A trend exists in targeting novel pathophysiological mechanisms in BD.
  • Preliminary results require further studies for clinical validation.